Brivaracetam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Brivaracetam
- Pharmacist Assessment Report
- Brivaracetam: SV2A-binding antiseizure medicine → beta-ketothiolase deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Brivaracetam: SV2A-binding antiseizure medicine → beta-ketothiolase deficiency
One-Sentence Summary
Brivaracetam is an antiseizure medicine marketed in Australia as an oral tablet. The TxGNN model predicts it may be relevant to beta-ketothiolase deficiency, but no clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | beta-ketothiolase deficiency |
| TxGNN Prediction Score | 0.9914 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Brivaracetam is generally understood to act through modulation of synaptic vesicle protein 2A (SV2A), but this is background knowledge and not drawn from the compiled data.
Beta-ketothiolase deficiency is an inherited metabolic disorder of ketone body and isoleucine breakdown. No clear mechanistic link to SV2A modulation was identified, apart from the possibility of seizures during metabolic decompensation. The high model score is likely an artefact of the model’s pattern-matching rather than evidence of a true pharmacological relationship. The similarity to the drug’s existing use has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11327E | Briviact | Tablet 25 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 69 potential interactions were recorded. Those listed as moderate include:
- Opioids and related agents: morphine (including liposomal), opium, diphenoxylate, difenoxin
- Cannabinoids: dronabinol, nabilone
- CNS-active or sedating agents: ethanol, promethazine, metoclopramide, sibutramine
- Antiplatelet: clopidogrel
- Minor interactions include proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole), sulfonylureas (chlorpropamide, tolbutamide) and cilostazol.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone. No trials or publications address beta-ketothiolase deficiency, and no plausible mechanistic link was identified.
To proceed, the following is needed:
- Mechanistic evidence linking brivaracetam to the pathophysiology of beta-ketothiolase deficiency
- Preclinical or clinical studies in this disease
- Product Information warnings and contraindications for a safety review
- Assessment of the clinical need, given that existing management of this condition is metabolic (dietary and acute-illness care)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.